Federal Hemp Regulation: 2018 Farm Bill, THC Limits & Industry Compliance

Executive Summary

Federal hemp regulation has become one of the most contentious battlegrounds in U.S. cannabis policy, pitting state-legal marijuana operators against hemp entrepreneurs in a fight over intoxicating cannabinoids derived from the cannabis plant. The 2018 Farm Bill legalized hemp—defined as cannabis containing no more than 0.3% delta-9 THC by dry weight—creating an unintended regulatory gap that allowed manufacturers to produce psychoactive products from hemp-derived compounds like delta-8 THC, THCA, and HHC. By 2026, the hemp-derived cannabinoid market has grown into a multi-billion dollar industry operating in a legal gray zone, with products sold in gas stations, convenience stores, and online retailers across states without marijuana programs. The resulting regulatory chaos has united unlikely opponents: state-licensed marijuana businesses concerned about unregulated competition, alcohol industry groups worried about market share, and lawmakers from both parties seeking to close what they view as a dangerous loophole. Meanwhile, hemp industry advocates argue that federal overreach threatens legitimate agricultural businesses and consumer access to wellness products. The debate centers on fundamental questions about the definition of hemp, the scope of FDA authority, state versus federal jurisdiction, and whether Congress intended the 2018 Farm Bill to create a parallel intoxicating cannabis market outside state regulatory frameworks.

Why Federal Hemp Regulation Matters

The federal hemp regulatory framework affects farmers in all 50 states, a $28 billion hemp industry, state marijuana programs serving 150 million Americans in legal markets, and millions of consumers purchasing hemp-derived products with minimal oversight. The stakes extend across multiple sectors. For agriculture, approximately 54,000 licensed hemp farmers depend on clear federal rules to plan crop cycles, secure financing, and access markets. The USDA reported 455,000 acres of hemp cultivation in 2025, representing $1.8 billion in farm gate value before processing. For these producers, regulatory uncertainty threatens their ability to obtain crop insurance, bank accounts, and distribution channels. State-licensed marijuana operators have invested over $20 billion in infrastructure, compliance systems, and tax payments since 2012. These businesses operate under strict seed-to-sale tracking, laboratory testing requirements, packaging restrictions, and effective tax rates exceeding 70% in some states due to Internal Revenue Code Section 280E, which prohibits normal business deductions for Schedule I controlled substances. They argue that hemp-derived intoxicating products create unfair competition from unregulated manufacturers who avoid these costs while selling functionally identical products. The alcohol industry views hemp-derived cannabinoids as a direct threat to beer and spirits sales, particularly among younger consumers. The Distilled Spirits Council reported that 18-34 year-olds reduced alcohol purchases by 12% in states with widespread hemp-derived THC availability, representing approximately $3.2 billion in displaced sales annually. Wine and beer trade associations have lobbied Congress for hemp restrictions, marking a rare alignment with marijuana industry interests. Public health officials express concern about products reaching minors through retail channels with minimal age verification. The FDA documented 2,847 adverse event reports related to delta-8 THC products between January 2021 and December 2025, including 892 cases involving individuals under 18. Poison control centers in states without marijuana programs reported 340% increases in pediatric cannabis exposures after hemp-derived products entered convenience stores. Consumer advocates emphasize that millions of Americans rely on hemp-derived CBD for pain management, anxiety, and sleep disorders, often in states without medical marijuana programs. Veterans groups have particularly championed hemp access, noting that 37% of VA patients in prohibition states use hemp-derived cannabinoids as alternatives to opioids or pharmaceuticals with severe side effects.

Background and History: From Prohibition to the 2018 Farm Bill

Federal hemp regulation traces back to the 1937 Marihuana Tax Act, which made no distinction between intoxicating and non-intoxicating cannabis, effectively prohibiting all cultivation until the 2018 Farm Bill created a narrow agricultural exception that entrepreneurs exploited far beyond congressional intent.

The Marihuana Tax Act and Controlled Substances Act Era (1937-2014)

The Marihuana Tax Act of 1937 imposed prohibitive taxes on all cannabis cultivation, processing, and sales, making no distinction between fiber hemp and drug cannabis. While the Act technically allowed hemp production under expensive licensing schemes, practical enforcement eliminated the American hemp industry by 1958. During World War II, the USDA briefly encouraged "Hemp for Victory" cultivation to replace Asian fiber imports, licensing 150,000 acres in 1943, but prohibition resumed after the war. The Controlled Substances Act of 1970 codified cannabis prohibition by placing marijuana in Schedule I of 21 U.S.C. § 812, defined as substances with high abuse potential, no accepted medical use, and lack of accepted safety for medical supervision. The CSA made no explicit hemp exception, leading the Drug Enforcement Administration to maintain that all cannabis cultivation remained federally illegal regardless of THC content. This interpretation survived legal challenges through the 1990s, with the DEA arguing that even sterilized hemp seeds and non-psychoactive hemp oil fell under Schedule I controls.

State Hemp Pilot Programs (2014-2018)

The 2014 Farm Bill (Agricultural Act of 2014, Section 7606) created the first federal hemp exception in 77 years, authorizing state departments of agriculture and higher education institutions to operate hemp research pilot programs. The provision defined hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis—a threshold borrowed from a 1976 Canadian taxonomy study by Ernest Small and Arthur Cronquist that distinguished fiber cultivars from drug varieties. By 2018, 41 states had established pilot programs licensing 3,546 farmers to cultivate 78,176 acres. Kentucky emerged as the leading producer with 6,700 licensed acres, followed by Colorado with 5,000 acres. The pilot programs focused primarily on CBD extraction, as entrepreneurs recognized that the 2014 Farm Bill's research language provided legal cover for commercial CBD production and sales despite FDA objections. The CBD market exploded from $350 million in 2014 to $4.6 billion in 2018, driven by testimonials about epilepsy treatment, pain relief, and anxiety reduction. This growth occurred in a regulatory vacuum, as the FDA maintained that CBD remained an unapproved drug and illegal food additive under the Federal Food, Drug, and Cosmetic Act, while the DEA insisted that CBD extraction from cannabis violated the CSA. Nevertheless, CBD products proliferated in health food stores, pharmacies, and online retailers with minimal enforcement.

The 2018 Farm Bill: Legalization and Unintended Consequences

The Agriculture Improvement Act of 2018, signed December 20, 2018, removed hemp from Schedule I and legalized cultivation, processing, and sales under USDA oversight. Section 10113 amended the Agricultural Marketing Act of 1946 to define hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." Senate Majority Leader Mitch McConnell championed the bill to support Kentucky tobacco farmers transitioning to hemp cultivation. The hemp provisions passed with bipartisan support, framed as agricultural policy rather than drug policy. Critically, the bill transferred regulatory authority from the DEA to the USDA for cultivation and left a gap regarding FDA oversight of hemp-derived products for human consumption. The 2018 Farm Bill explicitly preserved FDA authority under 21 U.S.C. § 331 and related statutes, noting that nothing in the hemp provisions affected FDA's jurisdiction over products containing cannabis or cannabis-derived compounds. However, the bill provided no funding or mandate for FDA hemp regulation, and the agency's subsequent inaction created a de facto unregulated market.

The Delta-8 THC Explosion (2019-2021)

Chemists quickly recognized that the 2018 Farm Bill's focus on delta-9 THC concentration created a loophole for other psychoactive cannabinoids. Delta-8 THC, a minor cannabinoid occurring naturally in cannabis at concentrations below 1%, produces intoxicating effects approximately 50-70% as potent as delta-9 THC. Manufacturers developed processes to convert CBD extracted from legal hemp into delta-8 THC through chemical isomerization using acids and heat. The first delta-8 THC products appeared in late 2019, marketed as "legal THC" or "diet weed." By mid-2020, delta-8 vape cartridges, gummies, and tinctures were available in smoke shops and online retailers nationwide. The market grew exponentially during the COVID-19 pandemic, reaching an estimated $2 billion in sales by December 2021. The DEA attempted to close the loophole through an Interim Final Rule published August 21, 2020, which stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The agency argued that chemically converting CBD into delta-8 THC constituted synthetic production, making the resulting compound illegal regardless of its hemp origin. However, the DEA provided no enforcement guidance, and the rule's legal interpretation remained disputed. Hemp industry attorneys argued that chemical conversion of one natural cannabinoid into another did not meet the statutory definition of "synthetic" under 21 U.S.C. § 802(6), which requires substances with chemical structures not found in natural plant materials.

State Responses and Market Fragmentation (2021-2024)

States responded inconsistently to hemp-derived intoxicating products. By January 2024, 17 states had banned delta-8 THC and similar compounds through emergency rules or legislation: Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Kentucky, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, Virginia, and Washington. These bans typically defined "intoxicating hemp products" to include any hemp-derived cannabinoid producing psychoactive effects, regardless of delta-9 THC content. Another 14 states implemented regulatory frameworks requiring laboratory testing, packaging restrictions, and retail licensing for hemp-derived cannabinoids while keeping them legal: California, Connecticut, Illinois, Louisiana, Maryland, Minnesota, Nevada, New Jersey, New Mexico, Ohio, Oklahoma, Oregon, Pennsylvania, and West Virginia. These regulations varied widely, with some states imposing marijuana-equivalent controls and others requiring only basic consumer protection measures. The remaining 19 states maintained no specific hemp-derived cannabinoid regulations beyond the 2018 Farm Bill's 0.3% delta-9 THC threshold, creating a patchwork where products legal in Alabama faced felony charges in Colorado. This fragmentation complicated interstate commerce, as hemp processors in unregulated states could not legally ship to states with bans, while retailers struggled to understand which products complied with which state laws.

THCA and the Next Wave of Loopholes (2023-2026)

As states closed the delta-8 loophole, hemp entrepreneurs identified THCA—tetrahydrocannabinolic acid, the non-intoxicating precursor to delta-9 THC found in raw cannabis—as the next opportunity. THCA converts to delta-9 THC through decarboxylation when heated (smoking, vaping, or cooking), but in its raw form contains no delta-9 THC. Hemp cultivators developed high-THCA strains that tested below 0.3% delta-9 THC when sampled but produced potent intoxicating effects when consumed. By 2024, THCA flower—visually and functionally identical to state-legal marijuana—was sold openly in hemp shops across prohibition states. A typical THCA hemp product contained 20-25% THCA by weight, which converted to approximately 17-21% delta-9 THC upon heating, matching or exceeding potency levels in state marijuana dispensaries. Prices ranged from $80-150 per ounce, significantly undercutting state-legal marijuana prices of $200-400 per ounce that included state excise taxes. The THCA market reached an estimated $5.3 billion in sales by 2025, with particularly strong growth in prohibition states like Texas, Georgia, and North Carolina. Hemp retailers in these states operated openly, advertising "legal weed" and "THC flower" while technically complying with the 0.3% delta-9 THC definition. State marijuana programs in New York, Illinois, and Michigan reported 15-30% sales declines in border counties adjacent to states with unregulated THCA hemp sales. Other hemp-derived intoxicating compounds entered the market during this period, including HHC (hexahydrocannabinol), THC-O (THC-O-acetate), and THCP (tetrahydrocannabiphorol). Each compound exploited the same regulatory gap: the 2018 Farm Bill only restricted delta-9 THC concentration, leaving all other cannabinoids unregulated regardless of psychoactive properties.

Key Players in the Federal Hemp Debate

United States Department of Agriculture

The USDA gained primary regulatory authority over hemp cultivation under the 2018 Farm Bill, publishing final rules October 31, 2021, that established licensing requirements, testing protocols, and compliance procedures. The USDA Hemp Production Program requires state and tribal plans to include sampling procedures testing for total THC (delta-9 THC plus 87.7% of THCA) within 15 days of harvest, disposal procedures for non-compliant plants, and licensing systems with background checks. The USDA has consistently maintained that its jurisdiction covers only cultivation and that the agency lacks authority to regulate hemp-derived products for human consumption. In testimony before the House Agriculture Committee in March 2025, Agriculture Secretary Tom Vilsack stated that "USDA's role ends at the farm gate" and called on Congress to clarify FDA authority over hemp-derived intoxicating products. The agency has licensed 54,000 hemp producers across 50 states and territories but has avoided taking positions on delta-8 THC, THCA, or other cannabinoid policy debates.

Food and Drug Administration

The FDA maintains authority over hemp-derived products for human consumption under the Federal Food, Drug, and Cosmetic Act but has largely failed to exercise regulatory control. The agency's position, articulated in numerous warning letters and public statements, holds that CBD and other cannabinoids are excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B) because they were investigated as drugs before being marketed as supplements. The FDA approved Epidiolex, a CBD-based epilepsy medication, in June 2018, which the agency argues precludes CBD's use in supplements or foods without formal approval processes. Despite this legal position, the FDA has issued only 48 warning letters to CBD manufacturers between 2019 and 2025, primarily targeting companies making explicit disease treatment claims. The agency has conducted no significant enforcement actions against delta-8 THC, THCA, or other hemp-derived intoxicating products, citing resource constraints and unclear congressional intent. FDA Commissioner Robert Califf told the Senate Health, Education, Labor and Pensions Committee in January 2026 that the agency needs "clear statutory authority and dedicated funding" to regulate the hemp-derived cannabinoid market effectively. The FDA has estimated that comprehensive hemp product regulation would require 150-200 additional full-time employees and $50-75 million in annual funding, resources Congress has not appropriated.

Drug Enforcement Administration

The DEA lost primary jurisdiction over hemp when the 2018 Farm Bill removed it from Schedule I but retains authority over synthetic cannabinoids and marijuana. The agency's August 2020 Interim Final Rule attempted to classify chemically converted hemp-derived cannabinoids as synthetic Schedule I substances, but the DEA has conducted minimal enforcement. Between 2020 and 2025, the agency executed only 12 enforcement actions specifically targeting delta-8 THC manufacturers, all involving operations that also violated state laws or produced products exceeding 0.3% delta-9 THC. DEA Administrator Anne Milgram testified before the Senate Judiciary Committee in November 2025 that the agency's position remains that "synthetically derived THC isomers are controlled substances," but acknowledged that "the legal ambiguity created by the 2018 Farm Bill has made enforcement challenging and resource-intensive." The DEA has called for congressional clarification rather than attempting aggressive enforcement of its synthetic cannabinoid interpretation.

State-Licensed Marijuana Industry

Multi-state marijuana operators and state cannabis trade associations have emerged as leading advocates for hemp restrictions, arguing that unregulated hemp-derived products undermine state regulatory frameworks and create unfair competition. The Cannabis Trade Federation, representing licensed operators in 25 states, has lobbied Congress for federal legislation defining "intoxicating hemp products" to include any hemp-derived cannabinoid producing psychoactive effects and subjecting such products to state marijuana regulations. Curaleaf, Trulieve, Green Thumb Industries, and other major MSOs reported combined revenue declines of 8-12% in 2025 compared to 2024, which executives attributed partially to hemp-derived product competition. In earnings calls, these companies have emphasized that they operate under strict testing requirements, packaging restrictions, advertising limitations, and tax burdens that hemp manufacturers avoid while selling functionally identical products. The National Cannabis Industry Association published a white paper in February 2026 arguing that THCA hemp flower violates the Controlled Substances Act because the total THC content exceeds 0.3% when measured post-decarboxylation. The organization has called for USDA testing protocols to measure total potential THC rather than only delta-9 THC in raw form.

Hemp Industry Trade Groups

The U.S. Hemp Roundtable, Hemp Industries Association, and National Hemp Association have defended the current regulatory framework, arguing that the 2018 Farm Bill legalized all hemp derivatives containing no more than 0.3% delta-9 THC and that Congress should not retroactively criminalize products that have been legal for years. These organizations represent approximately 8,000 hemp farmers, processors, and retailers with combined annual revenues exceeding $15 billion. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has argued that "the marijuana industry's complaints about competition are not a valid basis for re-prohibiting hemp products that Congress explicitly legalized." Hemp trade groups emphasize that many members produce non-intoxicating products like CBD wellness items, textiles, and hempcrete building materials, and that overly broad restrictions would harm legitimate agricultural businesses. These organizations have proposed self-regulatory frameworks including voluntary testing standards, age restrictions, and labeling requirements as alternatives to federal prohibition. The Hemp Industries Association published model state legislation in September 2025 that would require laboratory testing for contaminants, child-resistant packaging, and retail licensing while preserving hemp product legality.

Alcohol Industry Organizations

The Distilled Spirits Council, Beer Institute, and Wine Institute have lobbied for hemp restrictions, viewing cannabinoid products as competitive threats to alcohol sales. These organizations have funded research on cannabis-alcohol substitution effects and have coordinated with marijuana industry groups on legislative strategy—a rare alliance between traditional opponents. Chris Swonger, president of the Distilled Spirits Council, stated in April 2026 that "intoxicating products should be regulated consistently regardless of their source," and called for hemp-derived THC products to face the same state licensing, taxation, and retail restrictions as alcohol. The alcohol industry has emphasized public health concerns about unregulated intoxicants rather than explicitly acknowledging competitive concerns, but internal documents obtained through Freedom of Information Act requests revealed that trade associations tracked hemp sales data and market share impacts in presentations to member companies.

Congressional Champions and Opponents

Representative Chellie Pingree (D-ME) and Representative Mary Miller (R-IL) introduced the Hemp and Hemp-Derived Consumer Products Market Act in March 2026, which would prohibit hemp-derived products containing "any amount of total THC" from being sold outside state marijuana regulatory systems. The bill has attracted 67 cosponsors from both parties, including representatives from states with established marijuana programs and those concerned about youth access to intoxicating products. Senator Mitch McConnell (R-KY), the original 2018 Farm Bill hemp champion, has opposed restrictions on hemp-derived products, arguing that Kentucky farmers depend on the hemp industry for economic survival. McConnell stated in May 2026 that "we should not punish farmers and legitimate businesses because some actors have pushed boundaries" and called for targeted enforcement against bad actors rather than broad prohibitions. Representative James Comer (R-KY), chairman of the House Oversight Committee, has echoed McConnell's position, noting that Kentucky's hemp industry supports 15,000 jobs and generates $1.2 billion in economic activity. According to the May 18, 2026 newsletter from Marijuana Moment, Comer said that marijuana and alcohol industries oppose the hemp bill, characterizing their lobbying as protectionist rather than motivated by legitimate public health concerns. Senator Ron Wyden (D-OR) has proposed an alternative approach that would maintain hemp product legality while granting the FDA explicit authority and funding to establish testing standards, labeling requirements, and enforcement mechanisms. Wyden's discussion draft, circulated in April 2026, would appropriate $100 million annually for FDA hemp regulation and establish a 10% federal excise tax on hemp-derived intoxicating products to fund oversight.

Legal and Regulatory Framework

Federal hemp regulation operates at the intersection of the Controlled Substances Act, the Agricultural Marketing Act as amended by the 2018 Farm Bill, the Federal Food Drug and Cosmetic Act, and state police powers, creating jurisdictional ambiguities that no court has definitively resolved. The foundational statute is the Agricultural Improvement Act of 2018, Public Law 115-334, Section 10113, which amended the Agricultural Marketing Act of 1946 (7 U.S.C. § 1639o) to define hemp and remove it from Schedule I of the Controlled Substances Act (21 U.S.C. § 812). The definition specifies "delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis" as the sole cannabinoid threshold, making no mention of THCA, delta-8 THC, or other intoxicating compounds. The statute explicitly preserves FDA authority under Section 10114, stating that "nothing in this section or an amendment made by this section prohibits the Commissioner of Food and Drugs from issuing rules and regulations under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) that are more stringent than this section." However, the bill provided no appropriations for FDA hemp regulation, and the agency has argued that existing resources are insufficient for comprehensive oversight. The Controlled Substances Act remains relevant through 21 U.S.C. § 802(6), which defines "controlled substance analogue" and 21 U.S.C. § 813, which addresses temporary scheduling of synthetic substances. The DEA's position relies on these provisions to argue that chemically converted cannabinoids are synthetic Schedule I substances, but courts have not ruled on whether isomerization of one natural cannabinoid into another meets the statutory definition of "synthetic." State authority derives from the Tenth Amendment's reservation of police powers and the 2018 Farm Bill's Section 10113(b), which allows states to prohibit hemp production within their borders. Courts have consistently upheld state authority to ban or regulate hemp products more strictly than federal law, with the U.S. Court of Appeals for the Ninth Circuit ruling in Hemp Industries Association v. DEA, 333 F.3d 1082 (9th Cir. 2003), that states may regulate hemp even when federal law permits it. The Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) provides FDA authority over adulterated or misbranded foods, drugs, and dietary supplements. Section 321(ff)(3)(B) excludes from the dietary supplement definition any substance that was approved as a new drug or authorized for investigation as a new drug before being marketed as a supplement. The FDA argues this provision prohibits CBD in supplements because Epidiolex was investigated as a drug before CBD supplements entered the market, but this interpretation has not been tested in court regarding hemp-derived cannabinoids other than CBD. No federal court has issued a definitive ruling on the legality of delta-8 THC, THCA flower, or other hemp-derived intoxicating products under the 2018 Farm Bill framework. The closest judicial guidance came in AK Futures LLC v. Boyd Street Distro LLC, No. 21-cv-00066 (D. Or. 2022), where a federal district court assumed without deciding that delta-8 THC derived from hemp was legal under the 2018 Farm Bill for purposes of resolving a contract dispute. The court noted that "the legal status of delta-8 THC remains unsettled" but did not address the DEA's synthetic cannabinoid argument.

State-by-State Regulatory Approaches

States have adopted four distinct approaches to hemp-derived intoxicating products: complete prohibition, marijuana-equivalent regulation, hemp-specific frameworks, and federal-default permissiveness, creating a patchwork that complicates interstate commerce and consumer understanding.

Prohibition States

Alaska banned delta-8 THC and "chemically modified cannabinoids" through emergency regulations adopted by the Alcohol and Marijuana Control Office in September 2021, defining prohibited substances to include "any tetrahydrocannabinol other than delta-9 THC naturally occurring in cannabis." Violations are prosecuted as controlled substance offenses under Alaska Stat. § 11.71. Colorado prohibited hemp-derived intoxicating products through HB 21-1317, effective July 1, 2022, which defined "industrial hemp" to exclude "any part of the plant Cannabis sativa L. that is used or intended for use for human consumption and contains a total delta-9 THC concentration of more than 0.3 percent on a dry weight basis." The statute effectively bans THCA flower and delta-8 THC by measuring total THC rather than only delta-9 THC. Colorado's Marijuana Enforcement Division has issued 47 cease-and-desist orders to hemp retailers selling intoxicating products. Idaho maintained its complete cannabis prohibition, defining marijuana to include all cannabis regardless of THC content and refusing to recognize the 2018 Farm Bill's hemp exception. Idaho Code § 37-2701(t) defines marijuana as "all parts of the plant of the genus Cannabis" with no THC threshold, making all hemp products illegal. The Idaho State Police have arrested hemp transporters passing through the state, leading to ongoing litigation over interstate commerce rights. New York banned hemp-derived intoxicating products through emergency regulations adopted by the Office of Cannabis Management in September 2023, which prohibited "any cannabinoid, other than naturally occurring cannabidiol, derived from hemp that is intended for ingestion or inhalation and has psychoactive effects." The regulations allow CBD products but ban delta-8 THC, THCA, and similar compounds. New York has issued $2.3 million in fines to retailers selling prohibited hemp products.

Marijuana-Equivalent Regulation States

California integrated hemp-derived intoxicating products into its marijuana regulatory system through AB 45, effective January 1, 2024, which required all "cannabinoid products" producing intoxication to be manufactured by licensed cannabis businesses, tested by licensed laboratories, and sold through licensed dispensaries. The law defined "hemp product" to exclude any item containing "detectable amounts of tetrahydrocannabinol" that produces psychoactive effects. California's Department of Cannabis Control has conducted 156 enforcement actions against unlicensed hemp retailers. Illinois adopted similar integration through the Cannabis Regulation and Tax Act amendments effective June 1, 2023, requiring hemp-derived intoxicating products to meet all marijuana regulatory requirements including laboratory testing for potency and contaminants, child-resistant packaging, and sales through licensed dispensaries only. Illinois imposes a 10-25% excise tax on hemp-derived products sold through licensed channels, generating $18 million in revenue in 2025. Oregon required hemp-derived intoxicating products to be sold through Oregon Liquor and Cannabis Commission-licensed retailers under HB 3000, effective January 1, 2024. The law established a separate "hemp retailer" license category with less stringent requirements than marijuana dispensaries but mandatory age verification, product testing, and packaging standards. Oregon licensed 412 hemp retailers in 2025, generating $4.2 million in licensing fees.

Hemp-Specific Framework States

Minnesota created a comprehensive hemp-derived cannabinoid regulatory system through HF 4065, effective July 1, 2023, which legalized hemp-derived edibles containing up to 5 mg THC per serving and 50 mg per package, required laboratory testing and labeling, and established retail licensing through the Minnesota Department of Agriculture. The law distinguished between "hemp-derived consumer products" and marijuana, allowing the former in age-restricted retail locations including convenience stores and pharmacies. Minnesota licensed 2,847 hemp retailers in 2025. Ohio adopted hemp-derived cannabinoid regulations through the Department of Commerce in March 2024, requiring products to contain no more than 10 mg delta-9 THC per serving, pass laboratory testing for potency and contaminants, and be sold only to individuals 21 and older. Ohio does not require special retail licensing but mandates age verification and prohibits sales in locations primarily serving minors. The state has issued 89 cease-and-desist orders to retailers selling non-compliant products. Louisiana legalized hemp-derived THC products through HB 640, effective August 1, 2023, which authorized products containing up to 8 mg THC per serving, required testing and labeling, and established a Louisiana Department of Health permitting system for manufacturers and retailers. Louisiana issued 1,456 hemp product permits in 2025, generating $1.8 million in fees.

Federal-Default States

Nineteen states maintain no hemp-derived cannabinoid regulations beyond the 2018 Farm Bill's 0.3% delta-9 THC threshold: Alabama, Florida, Georgia, Indiana, Kansas, Missouri, Nebraska, New Hampshire, North Carolina, South Carolina, South Dakota, Tennessee, Texas, West Virginia, Wisconsin, and Wyoming. In these states, THCA flower, delta-8 THC, and other hemp-derived products are sold in smoke shops, convenience stores, and online retailers with no testing requirements, potency limits, or retail licensing. Texas has become the largest unregulated hemp market, with an estimated $2.1 billion in hemp-derived cannabinoid sales in 2025. The Texas Department of State Health Services has maintained that it lacks authority to regulate hemp products beyond the federal definition, and legislative attempts to establish regulations have failed in three consecutive sessions. Texas has approximately 4,500 retail locations selling hemp-derived intoxicating products, including major chains like Hometown Hero and Hometown CBD. Florida represents the second-largest unregulated market with $1.8 billion in estimated 2025 sales. Despite having a medical marijuana program, Florida has not restricted hemp-derived products, leading to widespread THCA flower sales in smoke shops and CBD stores. The Florida Department of Agriculture and Consumer Services has tested hemp products for compliance with the 0.3% delta-9 THC threshold but has not addressed THCA content or other intoxicating cannabinoids.

Market and Business Implications

The hemp-derived cannabinoid market reached $8.2 billion in 2025 sales, with THCA flower representing 42% of revenue, delta-8 THC products 31%, and other novel cannabinoids 27%, creating direct competition with the $31 billion state-legal marijuana market. Multi-state operators have experienced measurable revenue impacts in markets with unregulated hemp competition. Curaleaf reported that its Florida operations, the company's largest market, saw same-store sales decline 14% year-over-year in Q4 2025, which CEO Matt Darin attributed to "significant hemp-derived product competition at price points we cannot match while maintaining compliance with state regulations." Curaleaf's Florida dispensaries sold flower at $35-50 per eighth ounce ($280-400 per ounce) while hemp shops sold THCA flower at $15-25 per eighth ounce ($120-200 per ounce). Trulieve, which operates 185 dispensaries primarily in Florida, reported $127 million in revenue decline in 2025 compared to 2024, representing an 8% decrease. CEO Kim Rivers stated in the company's February 2026 earnings call that "unregulated hemp products have fundamentally altered competitive dynamics in our core markets" and that the company was evaluating whether to enter the hemp market despite concerns about regulatory risk. Green Thumb Industries reported more modest impacts in its diversified portfolio, with Illinois and New Jersey operations maintaining growth while Florida and Pennsylvania locations experienced declines. CFO Anthony Georgiadis noted that "states with clear hemp regulations like Illinois have not seen significant market disruption, while states with no hemp oversight have seen 15-20% market share loss to unregulated channels." Smaller single-state operators have faced more severe challenges. Several California dispensaries in border counties adjacent to Arizona have closed, citing competition from Arizona hemp shops selling THCA flower to California residents at prices 40-50% below California dispensary rates. The California Cannabis Industry Association documented 78 licensed retailer closures in 2025, with 34 operators citing hemp competition as a primary factor. Hemp industry participants have experienced rapid growth but face significant regulatory uncertainty. Hometown Hero, a Texas-based hemp-derived cannabinoid manufacturer, grew from $12 million in 2021 revenue to $187